BP-lowering treatment for patients with type 2 diabetes associated with improved mortality
the ONA take:
According to a new study published in JAMA, researchers have found that blood pressure-lowering treatment in patients with type 2 diabetes is associated with a decreased risk of cardiovascular disease and cardiovascular disease events, coronary heart disease events, and mortality.
For the meta-analysis, researchers identified 40 randomized controlled trials of blood pressure-lowering therapy conducted between 1966 and 2014 that included over 100,000 participants in order to investigate the associations between blood pressure-lowering treatment and cardiovascular disease in patients with type 2 diabetes.
Researchers found that each 10mm Hg lowering of systolic blood pressure was linked with a lower risk of cardiovascular disease events, coronary heart disease events, mortality, stroke, retinopathy, and albuminuria. Researchers did not find a significant difference in associations between blood-pressure lowering treatments and outcomes except for heart failure and stroke.
Results showed that blood pressure reduction below 130mm Hg was associated with a decreased risk of albuminuria, retinopathy, and stroke, but most outcomes had a decreased risk when systolic blood pressure was below 140mm Hg.
The findings supports current guideline recommendations that patients with type 2 diabetes be treated with antihypertensive therapy when their systolic blood pressure is above 140mm Hg.
Blood pressure-lowering treatment in patients with type 2 diabetes is associated with a decreased risk of cardiovascular disease.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|